Clinically reviewed by Dr. Sarah Boss, MD
Slow or absent breathing, collapse or inability to wake someone is an emergency. Call emergency services and use available naloxone according to its instructions. Do not switch between methadone and buprenorphine, restart after an interruption or calculate a dose conversion yourself.
Buprenorphine and methadone are established medicines for opioid use disorder. They can support a safer, more stable life by treating withdrawal and reducing craving, but they are not interchangeable prescriptions. The best option depends on clinical needs, previous treatment, other medicines and access to reliable care. A comparison should support an informed discussion, not encourage a self-directed switch or treat stopping medication as the only measure of recovery.
The purpose of treatment
Medication treatment is part of evidence-based care for opioid use disorder. CDC advises against detoxification alone without medication treatment because returning to opioid use after withdrawal can increase overdose risk. Completing a withdrawal episode and receiving continuing treatment are therefore different goals. [1]
Useful outcomes include avoiding overdose, reducing non-prescribed opioid use, improving health and participating in ordinary life. A person taking prescribed medication consistently can be making substantial progress. Treatment should also address housing, pain, mental health and relationships where relevant, rather than evaluating recovery solely by whether every prescription has ended.
Full and partial opioid agonists
Methadone is a full opioid agonist. Buprenorphine is a partial agonist with a different pattern of receptor activity and a ceiling to some effects. That difference is relevant to safety, but it does not make buprenorphine overdose-proof or mean methadone is an unsuitable treatment. Both require careful prescribing and review. [2] [3]
The individual buprenorphine and methadone profiles explain each medicine in more detail. Neither the agonist terminology nor the tablet number tells a reader which treatment fits their history. Previous benefit, adverse effects and practical access deserve equal attention.
Formulations and treatment settings
Buprenorphine products include preparations dissolved in the mouth and longer-acting injections used for opioid use disorder. Some products combine buprenorphine with naloxone. Pain patches and other pain formulations are not automatically substitutes for addiction-treatment products. The indication and delivery system must be checked together.
Methadone also comes in different preparations, and rules governing supply vary by country. Ask where treatment is provided, how prescriptions are coordinated and what happens if an appointment is missed. A theoretically suitable medicine is less useful when a person cannot reliably reach the service or maintain the agreed regimen. Availability should be confirmed locally rather than inferred from an international article. [3]
Starting buprenorphine requires an individual plan
Buprenorphine can displace other opioids from receptors and trigger precipitated withdrawal when started under unsuitable circumstances. The approach depends on previous opioid exposure, the person’s symptoms and the product. Fentanyl exposure, methadone treatment and complex substance use can make a generic internet waiting period particularly unhelpful.
This article gives no induction timetable. Tell the clinician what was used, when, and by which route, including prescribed opioids and medicines obtained elsewhere. Do not hide exposure to make starting treatment appear simpler. Accurate information allows the team to choose an appropriate strategy and respond if withdrawal or other problems occur. [2]
Methadone initiation and accumulation
Methadone’s effects can accumulate during repeated treatment. Its respiratory effects and persistence require particular care during initiation and after changes. Taking extra because withdrawal or pain has not settled can be dangerous. A prior prescription or past tolerance does not establish that a previous amount is safe after an interruption. [4]
The treatment service should explain how symptoms will be assessed, how changes are authorized and who is available between appointments. Report unexpected sleepiness, missed treatment and new medicines. Do not independently substitute another opioid while waiting for advice, and do not assume pain-treatment instructions apply to an opioid-use-disorder regimen.
Breathing risk and other sedatives
Alcohol, benzodiazepines, sleep medicines and other sedating substances can increase risk with either treatment. Breathing disorders and acute illness may add vulnerability. Slow or absent breathing, collapse or inability to wake someone requires emergency assistance. Use available naloxone according to its instructions while emergency help is obtained.
Interaction risk does not justify automatically withholding effective opioid-use-disorder treatment. FDA guidance emphasizes careful management when buprenorphine or methadone is used alongside benzodiazepines or other central nervous system depressants. The clinical task is to coordinate care and reduce risk, not leave opioid use disorder untreated. [5]
Heart rhythm and medication review
Methadone can prolong the QT interval and has important interactions with medicines that affect its metabolism or heart rhythm. Cardiac history, fainting, electrolyte disturbances and other prescriptions can influence monitoring. A clinician may arrange an electrocardiogram or blood tests based on the individual assessment. [4]
Buprenorphine also requires an interaction review; choosing it does not remove the need to consider other medicines. Bring psychiatric treatment, painkillers, antibiotics, supplements and any medicines obtained abroad into the discussion. A complete list is especially important when several services are involved and each sees only part of the prescribing history.
Dental care with medicines dissolved in the mouth
FDA has warned about dental problems with buprenorphine products dissolved in the mouth. It also emphasizes that their treatment benefits outweigh this risk. After the medicine has fully dissolved, gently rinse the mouth with water and swallow; wait at least an hour before brushing. Arrange dental care and report symptoms rather than stopping effective treatment independently. This warning is formulation-specific. [6]
Pain, mental health and daily functioning
Opioid use disorder can coexist with persistent pain, depression, trauma-related symptoms or anxiety. Each deserves assessment. Neither buprenorphine nor methadone should be described as a general antidepressant, and a stable addiction-treatment regimen does not remove the need for psychiatric care. The teams should agree how their treatment plans fit together.
Discuss sleep, constipation, concentration and any impairment affecting work or driving. Treatment that reduces illicit opioid exposure can create space for therapy and practical recovery work, but that does not mean every problem will resolve through medication alone. The co-occurring-care guide explains the coordination questions.
Pregnancy and continuity of care
Pregnancy calls for coordinated specialist care, not an independent detox or an abrupt stop. Tell the treatment team promptly about pregnancy or plans to conceive. The assessment should address opioid use disorder, other medicines, physical health and obstetric follow-up together. A comparison page cannot determine the appropriate pregnancy regimen.
Continuity also matters during hospital admission, residential treatment, travel and discharge. Confirm who supplies medication, how the receiving service verifies the regimen and what to do if access is interrupted. A clear handover can prevent duplicate prescribing and avoid an unintended gap that destabilizes otherwise effective care.
Physical dependence and treatment duration
Physical dependence can occur with prescribed opioid agonist treatment. It is not identical to uncontrolled addiction. The important distinction is how treatment affects health, safety and behavior. Taking a stable prescribed medicine to manage opioid use disorder should not automatically be characterized as replacing one failure with another.
Treatment duration is individualized and can be long term. Decisions about reduction should consider stability, preference, previous attempts, supports and overdose risk after loss of tolerance. There is no requirement in this guide to reach a medication-free endpoint. Continuing a helpful treatment can be a legitimate part of a recovery plan. [2]
Switching and missed treatment
Switching between these medicines needs a specialist plan. There is no safe personal milligram conversion, and the sequence can affect withdrawal and overdose risk. Do not combine supplies or resume an old regimen after missed treatment without contacting the service. Explain the actual interruption rather than reporting only the intended prescription.
Agree how to obtain help if cravings return or non-prescribed use occurs. A return to use should prompt a safety and treatment review rather than concealment or automatic exclusion from care. The opioid withdrawal and continuing-treatment guide explains why withdrawal management alone is not the whole plan.
Making treatment workable in everyday life
Discuss practical barriers before choosing or changing medication. These may include transport, opening hours, employment, caring responsibilities, privacy concerns or difficulty attending frequent appointments. A plan that appears straightforward on paper can become hard to sustain when those details are ignored. Ask the service which arrangements are actually available locally, rather than assuming that an option described in another country can be offered in the same way.
Review how the person will obtain help outside normal appointments. The plan should explain whom to contact after missed treatment, unexpected sedation, renewed cravings or a return to non-prescribed opioid use. It should also address safe storage and how people close to the patient can recognize an overdose and access appropriate emergency support, with the patient’s agreement. The aim is to make the next safe action clear before a difficult situation occurs.
When evaluating progress, include the person’s priorities. Keeping a job, reconnecting with family, attending healthcare and reducing the instability around obtaining opioids may be meaningful changes. A review should recognize those gains while still addressing ongoing risks. Medication decisions work best when they are connected to achievable goals and a reliable treatment relationship, not to an arbitrary deadline for ending all prescriptions.
Frequently asked questions
Is buprenorphine always safer?
Its pharmacology provides important safety differences, but combinations, formulation, exposure and individual health still matter. A medicine being safer in one respect does not establish the best overall treatment for everyone.
Does methadone mean treatment has failed?
No. It is an established treatment for opioid use disorder. Progress should be assessed through safety, health and functioning, not stigma attached to the medicine’s name.
Can someone change treatment for convenience?
Access and daily routines are valid reasons to discuss options. Any switch still needs clinical assessment and a coordinated prescription plan rather than self-substitution.
What should I ask before choosing?
Ask about the starting plan, monitoring, supply arrangements, other medicines, overdose prevention and how long-term review works. A choice should be understandable and feasible in everyday life.
Evidence and sources
- [1] CDC: Treating opioid use disorder.
- [2] SAMHSA: Buprenorphine.
- [3] SAMHSA: Methadone.
- [4] DailyMed: Methadone hydrochloride prescribing information.
- [5] FDA: Overdose-prevention timeline, September 2017 medication-management guidance.
- [6] FDA: Dental precautions for buprenorphine dissolved in the mouth.


